Abstract: Assay methods for analyzing whole blood to detect histamine H4 receptor-mediated effects, such as eosinophil shape change, cytoskeletal change, adhesion molecule up-regulation, or calcium flux are described. Such methods are useful in clinical and diagnostic applications.

Abstract: Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases or allergic conditions, including atopic allergic conditions, mediated by cathepsin S are described.

Abstract: A method for treating an allergic condition, including an atopic allergic condition, using substituted pyrazoles.

Abstract: The present invention relates to a method for monitoring the effect of in vivo administration of Cathepsin S inhibitors by measuring accumulation of an intermediate degradation product of invariant chain (Ii), in particular the p10 Ii fragment, in blood of dosed subjects.

Abstract: A method for treating an allergic condition, including an atopic allergic condition, using substituted pyrazoles.

Abstract: Heterocyclic compounds and methods of making them and using them.

Abstract: DNAs encoding monkey cathepsin S have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Abstract: DNAs encoding canine Cathepsin S have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Abstract: DNAs encoding monkey cathepsin S have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Abstract: DNAs encoding canine Cathepsin S have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Abstract: The present invention relates to the use of histamine H4 receptor modulators for the prevention, treatment, induction, or other desired modulation of inflammatory responses, inflammation, or diseases and/or conditions that are modulated, affected or caused by inflammation or inflammatory responses. The present invention also relates to the use of histamine H4 receptor modulators for the prevention, treatment, induction, or other desired modulation of polymorphonuclear leukocyte responses, such as migration to a particular site, or diseases and/or conditions that are modulated, affected or caused by polymorphonuclear leukocytes. The present invention also relates to the use of histamine H4 receptor modulators for the prevention, treatment, induction, or other desired modulation of mast cell responses, such as de-granulation, or diseases and/or conditions that are modulated, affected or caused by mast cells.

Abstract: The present invention relates to the use of histamine H4 receptor modulators for the prevention, treatment, induction, or other desired modulation of inflammatory responses, inflammation, or diseases and/or conditions that are modulated, affected or caused by inflammation or inflammatory responses. The present invention also relates to the use of histamine H4 receptor modulators for the prevention, treatment, induction, or other desired modulation of polymorphonuclear leukocyte responses, such as migration to a particular site, or diseases and/or conditions that are modulated, affected or caused by polymorphonuclear leukocytes. The present invention also relates to the use of histamine H4 receptor modulators for the prevention, treatment, induction, or other desired modulation of mast cell responses, such as de-granulation, or diseases and/or conditions that are modulated, affected or caused by mast cells.

Abstract: DNAs encoding monkey cathepsin S have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Abstract: DNAs encoding canine Cathepsin S have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Abstract: The present invention describes peptide substrates of the metalloproteases, ADAM8, ADAM15 and MDC-L. The invention also describes methods using these peptides to discover pharmaceutical agents that modulate these proteases. The invention further describes CD23 processing activity for these enzymes that may have important therapeutic implications for the use of inhibitors of these enzymes in allergic diseases such as asthma.

Abstract: The present invention relates to a method for monitoring the effect of in vivo administration of Cathepsin S inhibitors by measuring accumulation of an intermediate degradation product of invariant chain (Ii), in particular the p10 Ii fragment, in blood of dosed subjects.